Pricing Log in Create free account
Saturday 31 October 2026 Export JNJ’s income statement to Excel — free account

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

273.71 1.49 −0.54%
Market cap
$662.5B
P/E
31.7×
Fwd P/E
38.6×
Dividend yield
1.93%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Johnson & Johnson 10-Q filed Oct 21, 2026

Fiscal Q3 2026 · Period ended Sep 27, 2026 · Filed · accepted 4:18 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 23, 2026: 25 added · 29 removed · 35 modified; 27 with only figures updated; 6 moved without change

  1. Modified · Analysis of consolidated sales

    For the fiscal sixnine months of 2026, worldwide sales were $49.474.8 billion, a total increase of 8.27.4%, including an operational* increase of 6.0% as compared to 2025 fiscal sixnine months sales of $45.669.6 billion. Currency fluctuations had a positive impact of 2.21.4% for the fiscal sixnine months of 2026. In the fiscal sixnine months of 2026, acquisitions and divestitures had a net positive impact of 0.50.3%, on worldwide operational sales growth, primarily related to CAPLYTA. In the fiscal sixnine months of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.04.7%.